Table 5.
Multivariate analysis in non-diabetic NASH patients for developing advanced liver fibrosis.
| OR | 95%CI | p Value | AUC | Sensitivity (%) | Specificity (%) | ||
|---|---|---|---|---|---|---|---|
| Model 1 | Age | 1.11 | 1.03–1.23 | 0.017 | 0.89 | 80 | 83 |
| HOMA-IR | 1.56 | 1.09–2.50 | 0.033 | ||||
| PNPLA3 p.I148M and TM6SF2 p.E167K * | 31.29 | 2.16–2163.53 | 0.042 | ||||
| Model 2 | Age | 1.11 | 1.03–1.22 | 0.013 | 0.85 | 87 | 83 |
| HOMA-IR ≥ 3.02 | 2.79 | 0.48–22.43 | 0.275 | ||||
| PNPLA3 p.I148M and TM6SF2 p.E167K * | 8.77 | 1.12–193.81 | 0.074 | ||||
| Model 3 | Age | 1.14 | 1.05–1.26 | 0.004 | 0.89 | 80 | 83 |
| HOMA-IR ≥ 5.20 | 14.33 | 2.14–18.66 | 0.014 | ||||
| PNPLA3 p.I148M and TM6SF2 p.E167K * | 19.04 | 1.71–650.84 | 0.042 |
* At least one of the two polymorphisms.